CureToday: UC enrolling patients for glioblastoma trial
A new clinical trial at the University of Cincinnati is studying the effectiveness of a new two-pronged immunotherapy treatment procedure to treat the most aggressive and deadly type of brain tumors, called glioblastomas. Originating from healthy brain cells, glioblastomas can form in any area of the brain.
Soma Sengupta, MD, PhD, said the trial will administer two immunotherapy drugs in tandem with each other. She noted previous research has shown a single-arm immunotherapy treatment has not been effective, leading to the combination therapy being tested in the trial.
In collaboration with the Dana-Farber Cancer Insitute in Boston, a teaching affiliate of Harvard Medical School, researchers aim to enroll 24 patients in the Phase 1 study.
For more trial and enrollment information, contact Alex Love at lovea4@ucmail.uc.edu.
Featured photo at top of glioblastoma cells in culture courtesy of National Cancer Institute.
Related Stories
A family tradition continues at UC College of Nursing
April 24, 2026
When Ashley Enginger walks across the stage at this spring’s commencement ceremony, she will leave behind a UC College of Nursing that her family is far from finished with. Her sister Sarah is already two years in, and their youngest sister Lauren is set to arrive in the fall.
Rain, steep slopes put NY community at risk of landslides, geologist warns
April 23, 2026
UC Associate Professor Dan Sturmer tells News10 that heavy rain combined with steep slopes is a recipe for landslides in one New York community.
UC expands partnership with Thales for AI research
April 22, 2026
The University of Cincinnati’s interdisciplinary research facility Digital Futures welcomed its first industrial partner, Thales, at the beginning of Research + Innovation week. Thales is a global aerospace, defense and digital technology firm. Headquartered in France, it employs 83,000 people in dozens of countries, according to the Business Courier.